Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
ln Vitro |
In the human lung cancer cell line H1299, (E)-ferulic acid (0.03-0.6 mM, 24 h, 48 h) has modest anti-proliferative and anti-migration effects [1].
|
---|---|
ln Vivo |
(E)-ferulic acid can lessen the effects of tamoxifen on oxidation and nephrotoxicity when given intraperitoneally at a dose of 100 mg/kg for 21 days [2].
|
Cell Assay |
Cell proliferation analysis [1]
Cell Types: H1299 Tested Concentrations: 0.03- 0.6 mM Incubation Duration: 24 h, 48 h Experimental Results: There was no obvious cytotoxic effect at low doses, but cytotoxicity was observed at 0.3 and 0.6 mM 48 h. Apoptosis analysis [1] Cell Types: H1299 Tested Concentrations: 0.03-0.6 mM Incubation Duration: 48 h Experimental Results: The cell cycle was arrested at G0/G1 and the percentage of G2/M phase diminished. and induced a significant increase in the apoptotic population. Cell migration assay using 0.6 mM [1] Cell Types: H1299 Tested Concentrations: 0.03-0.6 mM Incubation Duration: 16 hrs (hours) (48 hrs (hours)) Experimental Results: Inhibition of cell migration and invasion. By reducing the activities of MMP-2 and MMP-9 and increasing β-catenin phosphorylation at Thr41/Ser45, it does not affect β-catenin protein levels. |
Animal Protocol |
Animal/Disease Models: Male Wister albino rat model [2]
Doses: 100 mg/kg Route of Administration: ig, one time/day for 21 days Experimental Results: Reduce the increase in AST, ALT and ALP enzyme activities caused by tamoxifen, and improve it Reduction in liver enzyme activity. |
References |
[1]. Fong Y, et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin Med. 2016 Oct 1;11:45.
[2]. Ogbuta A A, et al. Protective Effects of Trans-Ferulic acid on Tamoxifen Induced Heptatic and Renal Oxidative Stress in Male Wister Albino Rat. Journal of Applied Sciences and Environmental Management, 2023, 27(8): 1727-1732. |
Molecular Formula |
C10H10O4
|
---|---|
Molecular Weight |
194.1840
|
CAS # |
537-98-4
|
Related CAS # |
Ferulic acid;1135-24-6;Ferulic acid sodium;24276-84-4;(E)-Ferulic acid-d3;860605-59-0
|
SMILES |
O(C([H])([H])[H])C1=C(C([H])=C([H])C(/C(/[H])=C(\[H])/C(=O)O[H])=C1[H])O[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~514.99 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.1499 mL | 25.7493 mL | 51.4986 mL | |
5 mM | 1.0300 mL | 5.1499 mL | 10.2997 mL | |
10 mM | 0.5150 mL | 2.5749 mL | 5.1499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.